Navigation Links
Latest advances in interventional cardiology for congenital heart disease presented
Date:7/18/2008

Distinguished medical experts in the burgeoning field of interventional therapies for congenital and structural heart disease will gather in Las Vegas July 20-23 for the Pediatric & Adult Interventional Cardiac Symposium (PICS/AICS). Specialists from Rush University Medical Center in Chicago will perform live cases utilizing advance technologies during the course of symposium.

On Monday, July 21st, Dr. Ziyad M. Hijazi, director of the Rush Center for Congenital and Structural Heart Disease, will perform closure of an atrial septal defect (ASD) and patent ductus arteriosus closure. Hijazi is the course director and a founding member of PICS/AICS. He recently became the 31st president of the Society for Cardiovascular Angiography and Interventions (SCAI).

Several specialists from Rush will moderate or lead sessions, including a workshop about ASD involving Hijazi, Michel Ilbawi, chief of Pediatric Cardiac Surgery, and Zahid Amin, interventional cardiologist; a discussion about catheterizing critically ill infants led by Ilbawi, a breakout session about adult structural heart disease moderated by Dr. Cliff Kavinsky, interventional cardiologist; and a program on closure of ventricular septal defects by Amin.

In addition, specialists from Rush will present numerous studies, including information on the use of the Hemcon1 bandage to shorten the duration of bed rest following cardiac catheterization procedures, the safety of patent foramen ovale closure in elderly patients, and maternal and fetal outcomes following transcatheter device closure of ASD.

PICS/AICS 2008 is the most comprehensive symposium worldwide in the field of interventional therapies for congenital and structural heart disease in children and adults. The four-day conference brings together a select international faculty who provide demonstration, live operations and present the latest breakthroughs in their field. The symposium attracts more than 800 interventional cardiologists from more than 60 countries.

Hijazi is a pioneer in the non surgical repair of congenital heart defects. In addition to being widely published in his area of expertise, he has led groundbreaking national clinical trials of novel transcatheter closure devices for the treatment of ASD, ventricular septal defects, patent ductus ateriosys and patent foramen ovale. As a result of his research, the FDA approved the first ASD closure device for use in children in 2001.

Currently, Hijazi is evaluating percutaneous valve implantation for patients with defective pulmonary valves. In 2005, Hijazi became the first person in the United States to perform this innovative procedure.


'/>"/>

Contact: Kim Waterman
kimberly_waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Related biology news :

1. Iowa State professors genome research published in the latest issue of Science
2. Latest Integrated Microbial Genomes data management system update release
3. Leading researchers and experts gather to discuss latest advancements in drug discovery
4. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
5. Cardiologists and heart surgeons meet for Controversies and Advances conference
6. Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
7. Genetic Engineering & Biotechnology News reports on advances in miRNA
8. Prototype terahertz imager promises biochem advances
9. Science expands Science Signaling, featuring research related to medical advances, and more
10. Analysis of RNA role in spreading disease advances study of damaging plant infections
11. Iowa State-ConocoPhillips collaboration advances 26 research projects in first year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: